Disease · MONDO_0002670

ampulla of vater adenocarcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. ampulla of vater adenocarcinoma. Diseases, record MONDO_0002670. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002670

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: ampulla of vater adenocarcinoma; Open Targets
Open Targets ID: MONDO_0002670; Open Targets
Other names: adenocarcinoma of ampulla of Vater, ampullary adenocarcinoma, hepatopancreatic ampulla adenocarcinoma, invasive adenocarcinoma of the ampullary region; Open Targets
Disease Ontology: DOID:3502; Disease Ontology
NCI Thesaurus: C6650; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 6 of its 11 drugs, from ClinicalTrials.gov; Open Targets

Drugs11

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
OXALIPLATIN	CHEMBL414804	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
CAPECITABINE	CHEMBL1773	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
IRINOTECAN	CHEMBL481	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
FOLIC ACID	CHEMBL1622	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DOSTARLIMAB	CHEMBL4298124	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PANITUMUMAB	CHEMBL1201827	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
S1?	CHEMBL4525128		Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets

1 to 10 of 11

See all 11 drugs

Targets19

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TYMS	Thymidylate synthase	2	Thymidylate synthase inhibitor	Phase 3	https://conductscience.org/library/genes/7298	Drugs and targets
EGFR	Epidermal growth factor receptor	1	Epidermal growth factor receptor erbB1 inhibitor	Phase 2	https://conductscience.org/library/genes/1956	Drugs and targets
PDCD1	Programmed cell death protein 1	1	Programmed cell death protein 1 antagonist	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
POLA1	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 3	https://conductscience.org/library/genes/5422	Drugs and targets
POLA2	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 3	https://conductscience.org/library/genes/23649	Drugs and targets
POLD1	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 3	https://conductscience.org/library/genes/5424	Drugs and targets
POLD2	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 3	https://conductscience.org/library/genes/5425	Drugs and targets
POLD3	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 3	https://conductscience.org/library/genes/10714	Drugs and targets
POLD4	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 3	https://conductscience.org/library/genes/57804	Drugs and targets
POLE	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 3	https://conductscience.org/library/genes/5426	Drugs and targets

1 to 10 of 19

See all 19 targets

Trials8

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00354887	Capecitabine and Oxaliplatin in Adenocarcinoma of the Small Bowel and Ampulla of Vater	Phase 2	31	2011-07-14	Gastrointestinal Cancer	CAPECITABINE, OXALIPLATIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT01208103	Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma	Phase 2	30	2020-01-18	Ampulla of Vater Adenocarcinoma, Small Intestinal Adenocarcinoma, Stage III Ampulla of Vater Cancer AJCC v8, Stage III Small Intestinal Adenocarcinoma AJCC v8, Stage IIIA Ampulla of Vater Cancer AJCC v8, Stage IIIA Small Intestinal Adenocarcinoma AJCC v8, Stage IIIB Ampulla of Vater Cancer AJCC v8, Stage IIIB Small Intestinal Adenocarcinoma AJCC v8, Stage IV Ampulla of Vater Cancer AJCC v8, Stage IV Small Intestinal Adenocarcinoma AJCC v8	BEVACIZUMAB, CAPECITABINE, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT01202409	CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater	Phase 2	19	2020-02-21	Gastrointestinal Cancer	PANITUMUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT03800212	Survival and Description of Care for Patients With Degenerate Vaterian Ampulloma		402		Ampullary Adenocarcinoma	CAPECITABINE, FLUOROURACIL, GEMCITABINE, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT06068023	The ADAPTA Study: ADjuvant chemotherAPy After Curative Intent resecTion of Ampullary Cancer.		400		Ampullary Adenocarcinoma	CAPECITABINE, FLUOROURACIL, FOLINIC ACID, IRINOTECAN, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT06813976	PRODIGE 98 : Randomized, Multicenter Phase 3 Trial of Adjuvant Chemotherapy With Modified FOLFIRINOX Versus Capecitabine or Gemcitabine in Patients With Resected Ampullary Adenocarcinoma	Phase 3	294		Ampullary Adenocarcinoma	CAPECITABINE, FLUOROURACIL, FOLIC ACID, GEMCITABINE, IRINOTECAN, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT06333314	Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI	Phase 2	120		Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma, Neuroendocrine Carcinoma, Soft Tissue Sarcoma, Small Bowel Adenocarcinoma, Duodenum Adenocarcinoma, Gastric Adenocarcinoma	DOSTARLIMAB	Its record names the disease	ClinicalTrials.gov
NCT01180153	Study of S-1 Oxaliplatin (SOX) for Biliary Tract Cancer (BTC) (Ampullary Adenocarcinoma)	Phase 2	40		Biliary Tract Cancer	OXALIPLATIN	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
19164203	RESULT	1	PubMed
41812337	DERIVED	1	PubMed
41622055	DERIVED	1	PubMed
29259073	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002670

GET https://conductscience.org/api/diseases/v1/MONDO_0002670/drugs

API reference For AI assistants